3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Lung Neoplasms
13
Neoplasms
8
Melanoma
6
Neoplasm Metastasis
5
Head and Neck Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Large Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Advanced Non-Small Cell Lung Cancer
2
Adenocarcinoma
2
Vaccinia
1
Uterine Neoplasms
1
Interventions
Pemetrexed
7
Carboplatin
7
Cisplatin
5
pembrolizumab
4
durvalumab
4
osimertinib
3
Paclitaxel
3
selpercatinib
2
pralsetinib
2
cobimetinib
2
Radiosurgery
2
Erlotinib Hydrochloride
2
130-nm albumin-bound paclitaxel
2
trametinib
1
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
napabucasin
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
exemestane
1
enzalutamide
1
entinostat
1
dabrafenib
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
cemiplimab
×
Thoracic
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled